The secondary aim was to investigate whether MMP-9 levels correlate with severity of schizophrenic (assessed with the Positive and Negative Syndrome Scale (PANSS)) and depressive (assessed with the Calgary Depression Scale for Schizophrenia (CDSS)) symptoms and clinical improvement during our study. This evidence concerns the gene MMP9 and schizophrenia.